Laura Mosqueira-Martín

Dr. Laura Mosqueira-Martín

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
CVCamila Vesga-Castro
Camila Vesga-Castro
LMLaura Mosqueira-Martín
Laura Mosqueira-Martín
PUPaul Ubiria-Urkola
Paul Ubiria-Urkola
PMPablo Marco-Moreno
Pablo Marco-Moreno
KGKlaudia González-Imaz
Klaudia González-Imaz
JPJacobo Paredes
Jacobo Paredes
This 2D human muscle system, μGrooves, promote myoblast alignment and fusion and enhance myotubes differentiation. Robust high-content assays of functional outcomes, contractility and calcium, are made with increased sensitivity and reproducibility.

13 February 2025 in British Journal of Pharmacology
Verified
Journal Article
Open access
NGNúria Gaja-Capdevila
Núria Gaja-Capdevila
LMLaura Mosqueira-Martín
Laura Mosqueira-Martín
MHMireia Herrando-Grabulosa
Mireia Herrando-Grabulosa
LRLaura Rodriguez‐Gomez
Laura Rodriguez‐Gomez
KGKlaudia Gonzalez‐Imaz
Klaudia Gonzalez‐Imaz
FGFrancisco Gil-Bea
Francisco Gil-Bea
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target.Experimental Approach: A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the superoxide dismutase 1 (SOD1)G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy, including electrophysiology, histopathology, neuromuscular function and survival.Key Results: Among the novel FKBP12 ligands, MP‐010 was chosen for its central nervous system availability and favourable in vitro pharmaco‐toxicological profile. Chronic administration of MP‐010 to SOD1G93A mice produced preservation of motor nerve conduction, with the 61‐mg·kg−1 dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates and significant preservation of motor neurones in the spinal cord of treated mice. Notably, MP‐010 treatment significantly extended lifespan by an average of 10 days compared to vehicle.Conclusions and Implications: FKBP12 ligands, particularly MP‐010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.

20 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NGNúria Gaja-Capdevila
Núria Gaja-Capdevila
LMLaura Mosqueira-Martín
Laura Mosqueira-Martín
MHMireia Herrando-Grabulosa
Mireia Herrando-Grabulosa
KGKlaudia Gonzalez-Imaz
Klaudia Gonzalez-Imaz
ACAna Cristina Calvo
Ana Cristina Calvo
FGFrancisco Gil-Bea
Francisco Gil-Bea
SUMMARY: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons (MNs), characterized by dysregulated Ca 2+ influx and buffering in early ALS-affected MNs. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca 2+ , as a therapeutic target. A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the SOD1 G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy including electrophysiology, histopathology, neuromuscular function, and survival. Among the novel FKBP12 ligands, MP-010 was chosen for its central nervous system availability. Chronic administration of MP-010 to SOD1 G93A mice produced a dose-dependent preservation of motor nerve conduction, with the 61 mg/kg dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates, and significant preservation of MNs in the spinal cord of treated mice. Notably, MP-010 treatment significantly extended lifespan by an average of 10 days compared to vehicle. In conclusion, FKBP12 ligands, particularly MP-010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.

22 November 2024 in Cells
Verified
Journal Article
Open access
PDF file
MGMikel García-Puga
Mikel García-Puga
GGGorka Gereñu
Gorka Gereñu
ABAriadna Bargiela
Ariadna Bargiela
JEJorge Patricio Espinosa-Espinosa
Jorge Patricio Espinosa-Espinosa
LMLaura Mosqueira-Martín
Laura Mosqueira-Martín
Ander MatheuAnder Matheu
Ander Matheu
Background: Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder clinically characterized by progressive muscular weakness and multisystem degeneration, which correlates with the size of CTG expansion and MBLN decrease. These changes induce a calcium and redox homeostasis imbalance in several models that recapitulate the features of premature tissue aging. In this study, we characterized the impact of a new family of FKBP12 ligands (generically named MPs or MP compounds) designed to stabilize FKBP12 binding to the ryanodine receptors and normalize calcium dysregulation under oxidative stress. Methods: Human primary fibroblasts from DM1 patients and control donors, treated with MP compounds or not, were used for functional studies of cell viability, proliferation, and metabolism. The gene expression profile in treated cells was determined using RNA sequencing. The impact of MP compounds in vivo was evaluated in a Drosophila model of the disease using locomotor activity and longevity studies. Results: The treatment with different MP compounds reversed oxidative stress and impaired cell viability and proliferation, mitochondrial activity, and metabolic defects in DM1-derived primary fibroblasts. RNA sequencing analysis confirmed the restoration of molecular pathways related to calcium and redox homeostasis and additional pathways, including the cell cycle and metabolism. This analysis also revealed the rescue of alternative splicing events in DM1 fibroblasts treated with MP compounds. Importantly, treatment with MP compounds significantly extended the lifespan and improved the locomotor activity of a Drosophila model of the DM1 disease, and restored molecular defects characteristic of the disease in vivo. Conclusions: Our results revealed that MP compounds rescue multiple premature aging phenotypes described in DM1 models and decipher the benefits of this new family of compounds in the pre-clinical setting of DM1.